

REPROS THERAPEUTICS INC.

FORM 8-K (Current report filing)

Filed 11/13/17 for the Period Ending 11/13/17

Address	2408 TIMBERLOCH PL SUITE B-7 WOODLANDS, TX, 77380
Telephone	2817193400
CIK	0000897075
Symbol	RPRX
SIC Code	2836 - Biological Products, (No Diagnostic Substances)
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): November 13, 2017

Repros Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-15281
(Commission File Number)

76-0233274
(I.R.S. Employer Identification Number)

2408 Timberloch Place, Suite B-7, The Woodlands, Texas 77380
(Address of Principal Executive Offices) (Zip Code)

(281) 719-3400
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company []

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

[Exhibit 99.1](#). Press release dated November 13, 2017

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repros Therapeutics Inc.

Date: November 13, 2017

By: /s/ Kathi Anderson
Kathi Anderson
CFO

Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results

THE WOODLANDS, Texas, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2017.

Financial Results

Net loss for the three month period ended September 30, 2017, was (\$1.6) million or (\$0.04) per share as compared to a net loss of (\$4.2) million or (\$0.17) per share for the same period in 2016. The decreased loss for the three month period ended September 30, 2017, as compared to the same period in the prior year, was primarily due to decreased clinical development expenses related to the Company's Proellex® and enclomiphene product candidates, as well as decreased R&D payroll and benefits expenses and legal expenses. The Company recorded, in other income, a change in fair value of the warrant liability for the three month period ended September 30, 2017, in the amount of \$295,000.

Net loss for the nine month period ended September 30, 2017, was (\$9.7) million or (\$0.32) per share as compared to a net loss of (\$13.3) million or (\$0.55) per share for the same period in 2016. The decreased loss for the nine month period ended September 30, 2017, as compared to the same period in the prior year, was primarily due to decreased clinical development expenses related to the Company's Proellex® and enclomiphene product candidates, as well as decreased R&D payroll and benefits expenses and legal expenses, partially offset by expenses associated with the departure of the Company's former President and Chief Executive Officer.

For the three month period ended September 30, 2017, research and development ("R&D") expenses decreased 69%, or approximately \$2.2 million, to \$979,000, as compared to \$3.2 million for the same period in the prior year. For the nine month period ended September 30, 2017, R&D expenses decreased 59%, or approximately \$6.0 million, to \$4.2 million, as compared to \$10.2 million for the same period in the prior year. The decreases in both the three and nine month periods were primarily due to the decreased expenses related to the Company's Proellex® and enclomiphene product candidates in 2017, as well as decreased R&D payroll and benefits expenses and legal expenses.

General and administrative ("G&A") expenses decreased 6%, or approximately \$57,000, to \$940,000 for the three month period ended September 30, 2017, as compared to \$997,000 for the same period in the prior year and increased 81%, or approximately \$2.6 million, to \$5.7 million for the nine month period ended September 30, 2017, as compared to \$3.1 million for the same period in the prior year. The decrease in the three month period ended September 30, 2017, as compared to the same period in the prior year, was primarily due to decreased non-cash stock based compensation, partially offset by an increase in professional services. The increase in the nine month period ended September 30, 2017, as compared to the same period in the prior year, was primarily due to a charge of \$2.8 million related to the departure of the former officer, partially offset by a decrease in non-cash stock based compensation.

Total revenues and other income increased to \$304,000 for the three month period ended September 30, 2017 as compared to \$10,000 for the same period in the prior year. Total revenues and other income increased to \$158,000 for the nine month period ended September 30, 2017 as compared to \$41,000 for the same period in the prior year. The increases in revenues and other income in both periods were primarily due to the change in the fair value of the warrants issued by the Company in May 2017 during the three and nine month periods ended September 30, 2017. Excluding the change in the fair value of the warrants, revenues and other income decreased in both periods primarily due to lower cash balances during the three and nine month periods ended September 30, 2017, as compared to the comparable periods in the prior year.

Liquidity and Capital Resources

The Company had cash and cash equivalents of approximately \$1.8 million as of September 30, 2017 as compared to \$8.7 million as of December 31, 2016. Net cash of approximately \$8.5 million and \$12.5 million was used in operating activities during the nine month periods ended September 30, 2017 and 2016, respectively. The major use of cash for operating activities for the nine month period ended September 30, 2017 was to fund our clinical development programs and associated administrative costs. No cash was used in investing activities during the nine month period ended September 30, 2017. Cash provided by financing activities for the nine month period ended September 30, 2017 was approximately \$3.5 million primarily from the May Public Offering.

Nasdaq Listing

As disclosed by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 13, 2017, on November 8, 2017, the Company received notification from The NASDAQ Stock Market LLC that, pending a hearing, the Company's common stock will be delisted from Nasdaq. As further described in the Form 8-K, the Company intends to timely request a hearing before the Nasdaq Hearings Panel, which request will stay any suspension or delisting action by Nasdaq at least until the hearing process concludes and any extension granted expires. As such, the November 8, 2017 notice has no immediate effect on the listing of the common stock and the common stock will continue to trade on the NASDAQ Capital Market under the symbol "RPRX" at least until the hearing process concludes and any extension granted by the hearings panel expires.

As of September 30, 2017, we had 39,489,807 shares of common stock outstanding.

About Repros Therapeutics Inc.®

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Any such statements are based on current expectations that involve a number of known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such forward-looking statements, including the ability to have success in the clinical development of the Company's technologies, the reliability of interim results to predict final study outcomes, the ability to protect the Company's intellectual property rights and such

other risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at <http://www.reprosrx.com>.

Contact:

Investor Relations:

Joe Schepers
(770) 558-5517
jschepers@reprosrx.com

REPROS THERAPEUTICS INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited and in thousands except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2017	2016	2017	2016
Revenues and other income				
Interest income	\$ 9	\$ 10	\$ 23	\$ 41
Change in fair value of warrant liability	295	-	135	-
Total revenues and other income	304	10	158	41
Expenses				
Research and development	979	3,182	4,192	10,191
General and administrative	940	997	5,689	3,144
Total expenses	1,919	4,179	9,881	13,335
Net loss	\$ (1,615)	\$ (4,169)	\$ (9,723)	\$ (13,294)
Net loss per share - basic and diluted	\$ (0.04)	\$ (0.17)	\$ (0.32)	\$ (0.55)
Weighted average shares used in loss per share calculation:				
Basic	37,598	24,495	30,797	24,372
Diluted	37,598	24,495	30,797	24,372

CONSOLIDATED BALANCE SHEETS

(unaudited and in thousands)

	September 30, 2017	December 31, 2016
Current assets		
Cash and cash equivalents	\$ 1,813	\$ 8,688
Restricted cash	916	-
Prepaid expenses and other current assets	135	66
Total current assets	2,864	8,754
Fixed assets (net)	-	3
Non-current restricted cash	919	-
Total assets	\$ 3,783	\$ 8,757

Liabilities and stockholders' equityAccounts payable and accrued
expenses

\$ 2,438 \$ 2,659

Long-term liabilities

916 -

Warrant liability

1,716 -

Stockholders' equity

(1,287) 6,098

Total liabilities and

stockholders' equity

\$ 3,783 \$ 8,757